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Modeling Serum Biomarkers S100 Beta
and Neuron-Specific Enolase as Predictors
of Outcome After Out-of-Hospital Cardiac Arrest
An Aid to Clinical Decision Making
Sharon Einav, MD,*† Nechama Kaufman RN, MN,* Nurit Algur, MSC,* Jeremy D. Kark, MD, PHD‡
Jerusalem, Israel
Objectives The aim of this study was to determine the added value of the serum biomarkers S100 and neuron-specific eno-
lase to clinical characteristics for predicting outcome after out-of-hospital cardiac arrest.
Background Serum S100 beta (S100B) and neuron-specific enolase concentrations rise after brain injury.
Methods A prolective observational study was conducted among all adult survivors of nontraumatic out-of-hospital cardiac
arrest admitted to 1 hospital (April 3, 2008 to April 3, 2011). Three blood samples (on arrival and on days 1 and 3)
were drawn for biomarkers, contingent on survival. Follow-up continued until in-hospital death or discharge. Out-
comes were defined as good (Cerebral Performance Category score 1 or 2) or poor (Cerebral performance cate-
gory score 3 to 5).
Results A total of 195 patients were included (65.6% men, mean age 73  16 years), with presenting rhythms of asys-
tole in 61.5% and ventricular tachycardia or ventricular fibrillation in 24.1%. Only 43 patients (22.0%) survived to
hospital discharge, 26 (13.3%) with good outcomes. Patients with good outcomes had significantly lower S100B
levels at all time points and lower neuron-specific enolase levels on days 1 and 3 compared with those with poor
outcomes. Independent predictors at admission of a good outcome were younger age, a presenting rhythm of
ventricular tachycardia or ventricular fibrillation, and lower S100B level. Predictors on day 3 were younger age
and lower day 3 S100B level. The area under the receiver-operating characteristic curve of the admission-day
model was 0.932 with and 0.880 without biomarker data (p  0.027 for the difference).
Conclusions Risk stratification after out-of-hospital cardiac arrest using both clinical and biomarker data is feasible. The bio-
markers, although adding an ostensibly modest 5.2% to the area under the receiver-operating characteristic
curve, substantially reduced the level of uncertainty in decision making. Nevertheless, current biomarkers cannot
replace societal considerations in determining acceptable levels of uncertainty. (Protein S100 Beta as a Predic-
tor of Resuscitation Outcome; NCT00814814) (J Am Coll Cardiol 2012;60:304–11) © 2012 by the American
College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.020t
cHypoxic brain injury remains a leading cause of mortality
and morbidity after cardiopulmonary arrest with return of
spontaneous circulation (ROSC) (1,2). Survivors of cardiac
arrest often require lengthy intensive care admission, reha-
bilitation, and ongoing treatment of chronic complications
as a result of poor functional outcomes (3); however, correct
prediction of such outcomes remains elusive.
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012, accepted April 2, 2012.Protein S100 beta (S100B) is a calcium-binding protein
expressed mainly in human astroglial cells. Because astroglia
are as sensitive as neurons to hypoxia, serum S100B levels have
the potential to be a surrogate marker for neuronal damage and
damage to the blood-brain barrier. S100B is eliminated by the
kidneys (4) and has an estimated biological half-life of 2 h (5);
hus, constant elevation of S100B level in the serum reflects its
ontinuous release from damaged tissue.
See page 312
Neuron-specific enolase (NSE) is a dimer intracellular
enzyme of glucose metabolism localized predominantly in
neuronal cytoplasm (6). Serum NSE levels rise more slowly
than S100B levels but are more specific for neuronal damage
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July 24, 2012:304–11 Biomarkers to Predict Neurological Outcome of OHCA(7). The guidelines of the American Academy of Neurology
for predicting outcomes in comatose survivors of cardiac
arrest state that “serum NSE levels 0.33 mg/l at days 1–3 after
cardiopulmonary arrest accurately predict poor outcome”
(1). These guidelines, based on a systematic review of the
existing published research, state that there are insufficient
data to support or refute the use of other markers for
prognostication and recommend the performance of addi-
tional research on biomarkers.
S100B and NSE serum levels rise in clinical situations
reflecting each of the 3 classic models of brain injury:
hypoxia (8), trauma (9–11), and ischemia (12–16). In the
past decade, several commercial methods for measuring the
blood concentrations of both S100B and NSE have been
developed, making the use of these biomarkers technically
simple. Despite this, neither biomarker is being used in
clinical practice because of concerns regarding their discrim-
inant power.
The purpose of the present study was to determine how
biomarker and clinical data may be integrated to develop a
model for the early prediction of outcome at hospital
discharge and consequently to inform clinical decision
making (“outcome” meaning neurologically intact survival
vs. in-hospital death or survival with serious residual neu-
rological deficit). The hypothesis was that clinical and
laboratory characteristics, the latter determined by commer-
cially available kits and recorded at clinically convenient
times (on arrival, on the morning of day 1, and on the
morning of day 3) in a nonselective population can be used
to develop models for various levels of certainty in classifi-
cation. The timing of the blood draws was based on
previous observations regarding maximal increases in S100
and NSE levels after brain damage, which do not occur
concurrently (12–16). Because the present study’s aim was
to assess how joint modeling of clinical and biomarker data
may inform decision making, both biomarkers were in-
cluded to more fully capture the laboratory picture. The
models serve to demonstrate how clinicians may select the
likelihood of misdiagnosis (of a patient who would most
probably survive with a good neurological outcome) accept-
able in their clinical practice.
Methods
Within the framework of an extensive ongoing study of
nontraumatic out-of-hospital cardiac arrest (OHCA) in the
Jerusalem district, this prolective study was conducted over
a period of 3 years (April 3, 2008 to April 3, 2011). After
approval was obtained from the local institutional review
board, data were recorded in real time on all patients with
nontraumatic OHCA, age 18 years, who were brought
after ROSC to the Shaare Zedek Medical Center.
Clinical setting and inclusion and exclusion criteria. Shaare
Zedek Medical Center, the second largest hospital in the
Jerusalem district, is a 600-bed, university-affiliated acute
care facility. All patients with OHCA who underwent cattempted resuscitation within
the Jerusalem district and sur-
vived to admission to Shaare
Zedek Medical Center were eli-
gible for blood collection. Ex-
cluded were patients whose arrest
was triggered by acute hemor-
rhage, hanging, or drowning.
Definitions. OHCA was de-
fined as the absence of either
spontaneous respiration or palpa-
ble pulse or both, documented by
the national emergency medical
services while attending an emer-
gency call at any location within
the Jerusalem district that was
not an acute care facility. Arrival
was the time a patient was ad-
mitted to the hospital. Day 0 was
the day the event occurred (until
midnight). Day 1 was the day after the event occurred
(midnight to 11:59 PM); further days were defined accord-
ngly. A poor outcome was defined as a Cerebral Perfor-
ance Category (CPC) score of 3, 4 (severe neurological
mpairment), or 5 (death) at the time of hospital discharge.
good outcome was defined as a CPC score of 1 or 2 (good
o moderate neurological outcome) at the time of discharge
rom the hospital (17–19).
tudy protocol. No change was made in standard patient
herapy. Jerusalem district emergency medical services re-
uscitation is performed in accordance with American Heart
ssociation guidelines. All resuscitation attempts are re-
orded at the location of the arrest on standard forms by
mergency medical services staff members. Event data
ollection was in accordance with accepted guidelines (20).
dditional data were extracted on a daily basis from hospital
mergency department and admission files as required.
Contingent on patient survival, blood samples for serum
100B and NSE levels were drawn at the following times:
ospital arrival, the morning of day 1, and the morning of
ay 3. Because it was our intention to examine the value of
iomarker testing as part of routine patient treatment,
ampling times coincided either with the establishment of
ntravenous access or with routine blood testing for nonin-
estigational purposes.
Throughout the period of data collection, both treating
taff members and investigators were blinded to the results
f the investigational blood tests. Outcome was assessed
ithin the 24 h before discharge using the CPC score (21).
PC score was used as the instrument for assessing out-
ome because a high CPC score implies a very low likeli-
ood of a good Health Utilities Index score (22). CPC score
as assessed by a single trained research nurse (N.K.) and
as not recorded in the patient’s chart. Patients were
ollowed by study staff members until either hospital dis-
Abbreviations
and Acronyms
AUC  area under the
curve
CPC  Cerebral
Performance Category
NSE  neuron-specific
enolase
OHCA  out-of-hospital
cardiac arrest
ROC  receiver-operating
characteristic
ROSC  return of
spontaneous circulation
S100B  S100 beta
VF  ventricular fibrillation
VT  ventricular
tachycardiaharge or death, whichever occurred first.
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NSE were measured using the LIASON analyzer (Dia-
Sorin, Saluggia, Italy) using 2 different DiaSorin immuno-
metric chemiluminescence assays (sandwich principle) on
the basis of paramagnetic particles coated with monoclonal
antibodies and monoclonal tracer antibody labeled with an
isoluminol derivate. The light signal, and hence the amount
of isoluminol-antibody conjugate, is measured by a photo-
multiplier as relative light units and is indicative of the
sample concentration of S100B or NSE. Interassay coeffi-
cients of variation were 15% and 5% for S100B and
NSE, respectively.
Primary outcome measure. Poor versus good patient out-
come at discharge (see “Definitions”) was the measure used
to test the study hypotheses of improved prediction attrib-
utable to S100B and NSE concentration.
Statistical analysis. The study cohort included all enrolled
patients. Descriptive statistics were used for patient sociode-
mographic and event characteristics. Categorical variables
(e.g., patients’ sex and survival status) are expressed as
percents. Numerical variables (e.g., patient age, biomarker
levels) are presented with their means, standard deviations,
medians, interquartile range, and maximal and minimal
values. The nonparametric Friedman rank test was used for
within–outcomes group comparisons of biomarker levels at
the different sampling times, with correction of p values to
account for multiple testing.
Unadjusted differences between the 2 outcome groups
(poor outcome [CPC score 3 to 5] vs. good outcome [CPC
score 1 or 2]) in the biomarker variables (S100B and NSE
levels) were assessed using the Mann-Whitney U test
(because their distributions were not normal), with the
Bonferroni correction for multiple comparisons. Each of the
6 tests was performed with 1  0.05/6  0.0083. Bio-
arker data are presented using box plots.
The main analysis used multivariate logistic regression
odeling (forward stepwise) to predict the probability of a
oor outcome. Interactions between the presenting rhythm
f ventricular tachycardia (VT) or ventricular fibrillation
VF) and biomarker levels were sought and not found. After
etermining the acceptable specificity of the relevant com-
ination of variables for predicting a poor outcome (to
inimize the likelihood of misclassification of a patient
ith survival potential), prediction models for a poor out-
ome (yes or no) were created for day 0 (decision support for
he Department of Emergency Medicine) and for day 3
decision support for the intensive care unit or ward staff).
he day 0 model included all patients who contributed
lood samples on arrival. Explanatory variables were the
orresponding biomarker values and patient age, sex, and
resenting rhythm. The day 3 model included all survivors
o day 3 who had contributed 2 blood samples; to derive a
ore stable estimate, a model was created on the basis of the
4 observations available for days 1 and 3 rather than the 66
bservations available for admission and day 3. Explanatory
ariables included the biomarker values of samples 2 and 3;atient age, sex, and presenting rhythm; and treatment with
herapeutic hypothermia. Because of their non-normal dis-
ribution, biomarker levels underwent logarithmic transfor-
ation before inclusion in the models.
A receiver-operating characteristic (ROC) curve analysis
as performed for each model, yielding both an estimate of
he area under the curve (AUC) and cutoff values that can be
sed for prediction. DeLong’s 1-sided test was used to
ompare the ROC curves with the biomarker data to those
ithout. Data were analyzed using SPSS version 18.0
SPSS, Inc., Chicago, Illinois) and R version 2.13.1 (23,24).
esults
f the 250 patients who were screened, 55 patients were
xcluded because they arrived at the emergency department
n an agonal state, 195 were eligible for study inclusion, and
84 contributed blood samples. The demographic and event
etails of the eligible compared with the ineligible patients
re shown in Table 1. The eligible population was slightly
ounger but otherwise did not differ markedly from their
neligible counterparts.
Participants were mostly men (n  128 [65.6%]), with a
ean age of 73  16 years (range: 19 to 111 years). Their
resenting rhythm was most often asystole (n  120
61.5%]), VT or VF (n 47 [24.1%]), or pulseless electrical
ctivity (n  24 [12.3%]). Of the 195 patients studied, 39
ied in the emergency department, an additional 113
atients died later during admission, and 43 (17.2%) sur-
ived to hospital discharge. Thirty of the 47 patients who
resented with VF were treated with hypothermia.
lood samples. Biomarkers were sampled as follows: from
58 of the 195 patients on arrival (in 37 cases, the research
urse was not notified regarding patient arrival), 32 of
hom survived (20%), 19 with good outcomes (12%); from
01 of the 126 patients alive on day 1, 40 of whom survived
40%), 25 with good outcomes (25%); and from 74 of the 87
Patient CharacteristicsTable 1 Patient Characteristics
Characteristic
Eligible Patients
(n  195)
Ineligible Patients
(n  55) p Value
Age, yrs 72.9 16.0 77.1 11.9 0.033
Sex 0.13
Male 65.6% (128) 54.5% (30)
Female 34.4% (67) 45.5% (25)
Ethnicity 0.87
Jewish 88.7% (173) 89.1% (49)
Arab 10.3% (20) 9.1% (5)
Other 1.0% (2) 1.8% (1)
Presenting rhythm 0.75
Asystole 61.5% (120) 69.1% (38)
VT/VF 24.1% (47) 20% (11)
PEA 12.3% (24) 10.9% (6)
Other 2% (4) 0 (0)Values are mean  SD or % (n).
PEA  pulseless electrical activity; VF  ventricular fibrillation; VT  ventricular tachycardia.
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July 24, 2012:304–11 Biomarkers to Predict Neurological Outcome of OHCApatients alive on day 3, 37 of whom survived (50%), 24 with
good outcomes (32%) (Fig. 1).
S100B levels. Median levels were consistently higher at
ach time point in patients with poor outcomes (7.7, 1.8,
nd 1.4 g/l at admission, day 1, and day 3, respectively)
compared with patients with good outcomes (2.3, 0.3, and 0.2
g/l, respectively (p  0.0083 for each between-group com-
arison) (Fig. 2A).
Median S100B levels decreased sharply from admission
o day 1 within each group (corrected p  0.002 and p 
.006 for the poor and good outcomes, respectively). The
ithin-group change from admission to day 3 was steep in
oth groups (corrected p  0.002 and p  0.001, respec-
ively), whereas the decline from day 1 to day 3 was
inimal.
SE levels. Median levels at arrival did not differ signifi-
antly between patients with poor and good outcomes (37 and
8 g/l, respectively, p  0.059), but subsequently larger
ifferences emerged (35 vs. 22 g/l for day 1 and 61 vs. 16 g/l
for day 3) (p  0.0083 for days 1 and 3) (Fig. 2B).
NSE levels declined in patients with good outcomes
(Friedman rank test p  0.007) and increased in patients
with poor outcomes (p  0.022). Significant changes were
bserved in both groups on day 3, although in opposite
irections (corrected p  0.018 and p  0.008 for poor and
ood outcomes, respectively, for the difference between
rrival and day 3).
ay 0 model (n  158). Table 2 presents the factors
redicting a poor outcome on arrival. Model estimation
ithout the biomarkers (with age  67 or  67 years; i.e.,
he youngest age tertile) and VT or VF [yes or no] as the
nly explanatory variables) resulted in an AUC of 0.880
95% confidence interval: 0.806 to 0.954). In a model that
ncluded both biomarkers, the level of NSE became non-
ignificant, and the model retained only 3 significant vari-
bles: age, VT or VF, and the level of S100 at admission.
OC analysis performed on this model yielded an AUC of
.932 (95% confidence interval: 0.887 to 0.976) (Fig. 3).Figure 1 Flow Chart of Blood Samplingsing DeLong’s 1-sided test to compare the 2 correlated ROC
urves with and without S100 yielded a p value of 0.027.
The model was used to tabulate the probability cutoff
alues (for a poor outcome) with their respective sensitivi-
ies, specificities, and positive and negative predictive values
Online Appendix). For example, if the physician decides
hat specificity must be at least 0.90, then for patients with
alues above 0.92, we predict a poor outcome. The sensi-
ivity at this cutoff value was 0.79, and the exact specificity
as 0.95 (i.e., there is a 5% likelihood of misdiagnosing a
atient with a good prognosis).
Other cutoff values (that are meaningful to clinicians and
ocially acceptable) can be determined for selected values of
pecificity and sensitivity. For the aforementioned cutoff
alue of 0.92, we derived the inequality BX  ln [0.92/(1 
.92)] from the model of the poor outcome probability
stimated at admission (Pr) by the following:
Pr  expBX/1  expBX  0.92
And BX  b0  b1  VTVF  b2
 Age67_01  b3  lnS100 sample 1
 2.976 	 2.371  VTVF 	 1.743
 Age67_01  0.769  lnS100 sample 1
 Bconst  0.769  lnS100 sample 1
Where Bconst  2.976 	 2.371  VTVF 	 1.743  Age67_01
From this inequality, cutoff values for predicting a poor
outcome despite the achievement of ROSC and survival to
hospital admission for various combinations of our variables
may be determined (Table 3).
Day 3 model. Among the patients who survived to day 3,
the only variables to contribute independently to the model
were a presenting rhythm of VT or VF and the serum level
of S100B measured on day 3 (Table 4). ROC analysis
performed on the day 3 model yielded an AUC of 0.931
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Biomarkers to Predict Neurological Outcome of OHCA July 24, 2012:304–11(95% confidence interval: 0.873 to 0.989) (Fig. 4). Using the
same method as above (the table derived from this model is not
shown), we may determine that if the presenting rhythm was
not VT or VF, S100B  0.195 g/l predicts a poor outcome,
Figure 2
Serum S100B and NSE Levels (g/l) in Patients
With Good Outcomes and Patients With Poor
Outcomes
(A) Median S100 beta (S100B) levels on admission were 2.25 (interquartile range
[IQR]: 0.43 to 4.29; range: 0.15 to 19.40) and 7.66 (IQR: 3.39 to 15.40; range:
0.20 to 145.00) in patients with good and poor outcomes, respectively. Day 1 lev-
els were 0.30 (IQR: 0.18 to 0.71; range: 0.05 to 1.30) and 1.78 (IQR: 0.65 to
7.08; range: 0.20 to 124.00). Day 3 levels were 0.20 (IQR: 0.12 to 0.40; range:
0.10 to 0.50) and 1.40 (IQR: 0.51 to 5.62; range: 0.09 to 102.00). The p value
for the difference between patients with good and poor outcomes was 0.0083 at
all times. (B) Median neuron-specific enolase (NSE) levels on admission were
28.0 (IQR: 13.8 to 42.2; range: 8.5 to 253.0) and 36.9 (IQR: 23.4 to 52.6; range:
6.6 to 170.4) in patients with good and poor outcomes, respectively. Day 1 levels
were 21.7 (IQR: 14.9 to 31.7; range: 5.7 to 84.5) and 34.9 (IQR: 19.5 to 83.9;
range: 4.1 to 935.9). Day 3 levels were 15.6 (IQR: 8.65 to 19.9; range: 5.4 to
63.9) and 60.98 (IQR: 16.4 to 141.0; range: 7.0 to 436.4). NSE levels at admis-
sion were not significantly different between patients with good and poor outcomes
(p  0.059), but differences became larger on subsequent sampling (p  0.0083
for days 1 and 3).and if the presenting rhythm was VT or VF, serum S100B  l0.566 g/l predicts a poor outcome (sensitivity 0.86, specificity
.92).
iscussion
he present study demonstrates how modeling of clinical
ata together with neurological biomarker values can
ssist in predicting outcome after OHCA within ethically
cceptable safety margins. A local cohort of post-ROSC
atients provided pilot estimates of cutoff values for S100
evels on arrival to the emergency department. Although
iomarker data independently contributed an ostensibly
odest 5.2% to the AUC, they substantially reduced the
robability of misclassification error compared with that
ased solely on clinical criteria. When a presenting
hythm of VT or VF and the lowest age tertile were
dded as examples of key clinical covariates, cutoff values
or S100 could be tabulated with their specificity and
ensitivity characteristics and predictive values, providing
range of therapeutic limits to be discussed by ethicists
nd policy makers.
This study is unique in its examination of the effect size
f adding biomarkers to clinical data for prognostication
fter cardiac arrest. Previous studies of S100B and NSE
evels on hospital arrival included smaller sample sizes
13,14,25–28). Sampling of biomarkers at time of hospital
rrival is rarely performed; the few studies that did sample
100B at this time and sought outcomes other than death
lso identified significant between-group differences in
100B levels at this time (13,14,25). Although a larger
umber of studies have examined NSE levels on arrival,
heir findings were not definitive (29). The present study
akes the additional step of demonstrating how these data
an be used by clinicians; all patients were sampled at the
ime of routine blood testing, and no change was made in
are to emulate a real-life situation. In most studies, S100B
nd NSE were sampled at preset times after suspected onset
f cardiac arrest. Our study end point was differentiation
etween poor and good outcomes, the latter including only
urviving patients with good neurological outcomes. Shino-
aki et al. (29) found 16 studies addressing the clinical
sefulness of NSE or S100B as a prognostic predictor of
eurological outcomes and 5 of functional outcomes; rarely
id any study that involved blood sampling both on arrival
nd as an integral part of routine care (rather than at
re-specified times from arrest or ROSC) also seek an
utcome other than death.
Several studies have merged biomarker and clinical data.
ingler et al. (25) investigated NSE and S100B on days 1,
, 3, and 7 as well as somatosensory-evoked potentials
ecorded within 48 h and on day 7 after ROSC (n 27) but
id not integrate these data into a single model. Prohl et al.
30) performed a multivariate logistic regression analysis of
SE and S100B levels together with standardized clinical
xaminations (days 2 to 4) and short-latency and long-
atency somatosensory-evoked potentials (n  80). They
ions as
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July 24, 2012:304–11 Biomarkers to Predict Neurological Outcome of OHCAconstructed a model in which 85% of the variance in the
neurological outcome (dichotomized Glasgow-Pittsburgh
CPCs) was explained by age together with the clinical
examination score and the level of NSE on day 4. Grubb et
al. (31) performed a multiple regression on S100B and NSE
concentrations (sampled within 24 to 48 h of ROSC), age,
a social deprivation score, National Adult Reading Test
score, and a local clinical prognostic score (including a
presenting rhythm of VT or VF, bystander cardiopulmonary
resuscitation, and Glasgow Coma Scale score on admis-
sion). They found that NSE and S100 concentrations were
significant independent predictors of the Rivermead Behav-
ioural Memory Test score, which was the principal outcome
measure in their study (n  105).
NSE levels on arrival do not consistently correlate with poor
outcomes (29). It is therefore unsurprising that determination
of NSE in addition to S100B at this time did not improve the
Figure 3 ROC Analysis for Day 0 Model (n  158)
The model included 3 significant variables: age (67 or 67 years), ventricular
tachycardia or ventricular fibrillation as the presenting rhythm (yes or no), and
level of S100 beta sampled on hospital arrival. The area under the receiver-
operating characteristic (ROC) curve is 0.932 (95% confidence interval: 0.887
to 0.976).
Predictors at Admission of a Poor Outcome (n  158)Table 2 Predictors at Admission of a Poor Outcome (n  158)
Variable
Univariate Analysis
Odds Ratio‡ (95% CI) p Value Od
Age (continuous) 1.07 (1.03–1.11) 0.001
Age 67 yrs 0.10 (0.03–0.32) 0.001 N
Sex 0.21 (0.66–6.69) 0.21 N
VT/VF 0.06 (0.02–0.185) 0.001
ln(admission S100B) 2.44 (1.62–3.67) 0.001
ln(admission NSE) 2.05 (0.95–4.41) 0.068
The variables included in the model were patient age (continuous variable in model 1 and divided
on admission. *Negative 2 log likelihood  64.7, Cox and Snell R2  0.277, and Nagelkerke R2 
odds ratios are for a 1-SD change.
CI  confidence interval; NSE  neuron-specific enolase; S100B  S100 beta; other abbreviatlikelihood of a correct prediction. However, NSE rises more
slowly than S100B and should therefore have been of value in
the day 3 model. Our seemingly unexpected finding may stem
from the large number of in-hospital deaths, which led to a
small sample size and hence limited power for the day 3
analyses. We also a priori selected the model on the basis of a
greater number of cases (day 3 rather than day 1) to achieve a
more stable estimate; in this model, NSE was not contributory.
However, others have also suggested that S100B may be the
better marker of the 2 (32).
Study limitations. The present study had several limita-
tions, the key one being the need for a larger sample size to
generate stable probability estimates. Several investigators
have suggested that the time courses of S100B and NSE
may provide more useful information than isolated sampling
(29,31). We found no advantage to this method as assessed
by repeated-measures analysis, perhaps because of the high
in-hospital mortality rates in our sample, which diminished
our sample size and thus the study power for day 3 analysis.
A multicenter study is needed to increase both the stability
(i.e., sample size) and the generalizability of the estimates.
Lack of a validation cohort limits drawing stable inferences
regarding survival from the sample reported here. However,
a goal of this study was to demonstrate how joint modeling
of clinical and biomarker data may inform the design of
future analyses on substantially larger datasets.
ivariate Analysis, Model 1* Multivariate Analysis, Model 2†
tio‡ (95% CI) p Value Odds Ratio‡ (95% CI) p Value
.02–1.12) 0.007 Not relevant to model —
vant to model — 0.18 (0.05–0.67) 0.011
e model — Not in the model —
.02–0.29) 0.001 0.09 (0.03–0.33) 0.001
.12–3.12) 0.017 2.14 (1.29–3.54) 0.003
.01–10.30) 0.048 Not significant —
les in model 2), VT or VF as the presenting rhythm (yes or no), and serum levels of S100 and NSE
. †Negative 2 log likelihood  67.0, Cox and Snell R2  0.267, and Nagelkerke R2  0.514. ‡All
in Table 1.
Example of Cutoff Values for S100Bon Arrival (Day 0 Model), Determinedfor Specificity of 0.95 and Sensit vity of 0.79
Table 3
Example of Cutoff Valu s for S100B
on Arrival (Day 0 Model), Determined
for Specificity of 0.95 and Sensitivity of 0.79
Presenting Rhythm Age (yrs) Cutoff Value for Admission S100B
Not VT/VF 67 0.55
Not VT/VF 67 4.99
VT/VF 67 11.04
VT/VF 67 107.88
For patients whose S100 values on emergency department arrival exceed specific cutoff values
(determined by age group [67 or 67 years] and with or without VT or VF), a poor outcome can
be predicted despite achievement of return of spontaneous circulation and survival to hospitalMult
ds Ra
1.07 (1
ot rele
ot in th
0.07 (0
1.87 (1
3.23 (1
by terti
0.533admission.
S100B  S100 beta; other abbreviations as in Table 1.
S100 b
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Most studies of biomarkers in post-ROSC patients seek
simple cutoff points, ignoring patient demographic and
clinical characteristics. Few clinicians would agree to cease
ongoing resuscitation efforts on the basis of the results of
blood tests alone. However, many physicians would not
hesitate to modify treatment in accordance with the likeli-
hood of success. Stratification based on combined clinical
and laboratory data should thus be the preferred clinical
approach for the interpretation of biomarkers of brain
damage. This said, modeling still cannot replace societal
responsibility in determining the acceptable level of uncer-
tainly in decision making. Parallel to searching for the
infallible brain biomarker, policy makers should determine
Predictors on Day 3 of a Poor Outcome (n  74Table 4 Predictors on Day 3 of a Poor Outc
Variable
Univariate Ana
Odds Ratio† (95% CI)
Age (continuous) 1.06 (1.024–1.10)
Sex 1.48 (0.46–4.726)
VT/VF 0.143 (0.047–0.43)
Therapeutic hypothermia 0.46 (0.17–1.265)
ln(S100B) on day 1 5.554 (2.23–13.815)
ln(NSE) on day 1 1.836 (0.94–3.576)
ln(S100B) on day 3 7.346 (2.66–20.27)
ln(NSE) on day 3 4.74 (2.07–10.84)
The variables included in the model were patient age, sex, VT/VF as th
or no), and the serum concentrations of S100B and NSE sampled on
and Nagelkerke R2  0.652. †All odds ratios are for a 1-SD change.
CI  confidence interval; NSE  neuron-specific enolase; S100B 
Figure 4 ROC Analysis for Day 3 Model (n  74)
The model included 2 significant variables: ventricular tachycardia or ventricular
fibrillation as the presenting rhythm (yes or no) and level of S100 beta sam-
pled on day 3. The area under the receiver-operating characteristic (ROC) curve
is 0.931 (95% confidence interval: 0.873 to 0.989).the level of risk for misclassification acceptable to society
within this clinical setting.
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